Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

VIRTUUS Children's Study (VIRTUUS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03719339
Recruitment Status : Active, not recruiting
First Posted : October 25, 2018
Last Update Posted : April 8, 2020
Sponsor:
Collaborator:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Information provided by (Responsible Party):
Children's Hospital of Philadelphia

Brief Summary:
The objective of the VIRTUUS Children's Study is to adapt identified and validated adult noninvasive diagnostic and prognostic biomarkers for the characterization of allograft status in pediatric recipients of kidney allografts.

Condition or disease
Renal Transplant Rejection Pediatric Kidney Disease End Stage Renal Disease Nephropathy BK Virus (Nephropathy) Antibody-mediated Rejection Acute Cellular Graft Rejection

Show Show detailed description

Layout table for study information
Study Type : Observational
Estimated Enrollment : 450 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Validating Injury to Renal Transplant Using Urinary Signatures in Children
Actual Study Start Date : August 10, 2017
Estimated Primary Completion Date : May 31, 2022
Estimated Study Completion Date : April 30, 2023



Primary Outcome Measures :
  1. Amount of CD3E mRNA (CD3-epsilon polypeptide) [ Time Frame: 48 months ]
    The amount of mRNA observed in urinary sample biopsy.

  2. Amount of CXCL10 (chemokine C-X-C motif ligand 10) [ Time Frame: 48 months ]
    The amount of mRNA observed in urinary sample biopsy.

  3. Amount of 18s rRNA [ Time Frame: 48 months ]
    The amount of mRNA observed in urinary sample biopsy.


Biospecimen Retention:   Samples With DNA
Blood, sputum, urine, tissue


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population
Subjects 2 to 18 years of age meeting inclusion criteria will be recruited from the participating sites' Nephrology outpatient clinics or inpatient settings. All sites may choose to enroll Spanish speaking subjects pending the site has necessary resources to translate/interpret study related information. Sites choosing to enroll Spanish speaking subjects will have a native speaking translator or interpreter available to prevent any miscommunication during the consent process.
Criteria

Inclusion Criteria:

  • Males or females between 2 to 18 years at the time of recruitment
  • Receiving the first, or additional, incident kidney transplants.
  • Have an existing/prevalent transplant with a scheduled kidney allograft biopsy.
  • Parental/guardian permission (informed consent) and, if appropriate, child assent.

Exclusion Criteria:

• Patient's primary medical team feels the subject's participation is not safe.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03719339


Locations
Layout table for location information
United States, California
Children's Hospital Los Angeles
Los Angeles, California, United States, 90027
University of California
Los Angeles, California, United States, 90095
Stanford University
Palo Alto, California, United States, 94304
United States, Illinois
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States, 60611
United States, Minnesota
University of Minnesota
Minneapolis, Minnesota, United States, 55455
United States, Ohio
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States, 45229
United States, Pennsylvania
CHOP
Philadelphia, Pennsylvania, United States, 19104
United States, Washington
Seattle Children's Hospital
Seattle, Washington, United States, 98105
Sponsors and Collaborators
Children's Hospital of Philadelphia
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Investigators
Layout table for investigator information
Principal Investigator: Brendan Keating, DPhil Children's Hospital of Philadelphia and Hospital of The University of Pennsylvania
Layout table for additonal information
Responsible Party: Children's Hospital of Philadelphia
ClinicalTrials.gov Identifier: NCT03719339    
Other Study ID Numbers: 17-013841
1R01HD091185-01 ( U.S. NIH Grant/Contract )
First Posted: October 25, 2018    Key Record Dates
Last Update Posted: April 8, 2020
Last Verified: April 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Keywords provided by Children's Hospital of Philadelphia:
Kidney disease
Kidney allograph
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Kidney Failure, Chronic
Urologic Diseases
Renal Insufficiency, Chronic
Renal Insufficiency